Jeffrey Bennett
Concepts (557)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 88 | 2026 | 137 | 19.030 |
Why?
| | Aquaporin 4 | 61 | 2026 | 98 | 9.100 |
Why?
| | Multiple Sclerosis | 36 | 2026 | 485 | 5.990 |
Why?
| | Autoantibodies | 52 | 2026 | 1505 | 4.950 |
Why?
| | Immunoglobulin G | 52 | 2024 | 886 | 4.270 |
Why?
| | Optic Neuritis | 15 | 2023 | 44 | 3.950 |
Why?
| | Antibodies, Monoclonal, Humanized | 25 | 2026 | 990 | 2.940 |
Why?
| | B-Lymphocytes | 17 | 2026 | 875 | 2.220 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 17 | 2024 | 54 | 1.670 |
Why?
| | Immunologic Factors | 7 | 2026 | 259 | 1.670 |
Why?
| | Astrocytes | 16 | 2026 | 228 | 1.620 |
Why?
| | Optic Nerve | 12 | 2023 | 67 | 1.570 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 49 | 1.460 |
Why?
| | Remyelination | 2 | 2025 | 15 | 1.450 |
Why?
| | Complement Inactivating Agents | 4 | 2026 | 75 | 1.320 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 28 | 1.320 |
Why?
| | Neuroglia | 5 | 2024 | 173 | 0.990 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 84 | 0.970 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1505 | 0.940 |
Why?
| | Tomography, Optical Coherence | 7 | 2023 | 270 | 0.940 |
Why?
| | Complement C5 | 1 | 2025 | 33 | 0.900 |
Why?
| | Immunosuppressive Agents | 8 | 2026 | 834 | 0.900 |
Why?
| | Humans | 152 | 2026 | 144667 | 0.890 |
Why?
| | Brain | 13 | 2026 | 2934 | 0.880 |
Why?
| | Magnetic Resonance Imaging | 16 | 2026 | 3888 | 0.870 |
Why?
| | Macaca mulatta | 8 | 2024 | 186 | 0.850 |
Why?
| | Epitopes | 8 | 2025 | 479 | 0.840 |
Why?
| | Cerebellum | 4 | 2025 | 224 | 0.820 |
Why?
| | Retinal Degeneration | 2 | 2023 | 39 | 0.810 |
Why?
| | Natalizumab | 4 | 2020 | 41 | 0.780 |
Why?
| | Complement System Proteins | 7 | 2019 | 314 | 0.780 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 4 | 2023 | 68 | 0.780 |
Why?
| | Animals | 67 | 2026 | 37948 | 0.770 |
Why?
| | Methylprednisolone | 1 | 2023 | 58 | 0.770 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 31 | 0.740 |
Why?
| | Disease Models, Animal | 16 | 2025 | 4539 | 0.700 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 85 | 0.690 |
Why?
| | Blood-Brain Barrier | 5 | 2022 | 155 | 0.690 |
Why?
| | Autoimmunity | 4 | 2017 | 930 | 0.680 |
Why?
| | Myelin Sheath | 7 | 2025 | 169 | 0.660 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 39 | 0.640 |
Why?
| | Immunotherapy | 4 | 2020 | 662 | 0.620 |
Why?
| | Adult | 48 | 2026 | 40489 | 0.620 |
Why?
| | Complement C1q | 1 | 2019 | 32 | 0.590 |
Why?
| | Middle Aged | 45 | 2026 | 35971 | 0.580 |
Why?
| | Complement Activation | 4 | 2022 | 409 | 0.580 |
Why?
| | Plasma Cells | 7 | 2017 | 79 | 0.580 |
Why?
| | Mice | 34 | 2026 | 18261 | 0.580 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 24 | 0.570 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 32 | 0.570 |
Why?
| | Glial Fibrillary Acidic Protein | 5 | 2024 | 125 | 0.570 |
Why?
| | Cell Membrane | 3 | 2017 | 706 | 0.560 |
Why?
| | Papilledema | 4 | 2023 | 44 | 0.560 |
Why?
| | Inflammation | 11 | 2023 | 2870 | 0.550 |
Why?
| | Aminopyridines | 1 | 2019 | 129 | 0.550 |
Why?
| | Central Nervous System | 5 | 2023 | 279 | 0.550 |
Why?
| | Female | 68 | 2026 | 78304 | 0.540 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 82 | 0.540 |
Why?
| | Organic Chemicals | 1 | 2019 | 126 | 0.540 |
Why?
| | Pyrroles | 1 | 2019 | 213 | 0.530 |
Why?
| | Double-Blind Method | 10 | 2025 | 2033 | 0.530 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 337 | 0.530 |
Why?
| | Glucocorticoids | 2 | 2019 | 528 | 0.520 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 50 | 0.520 |
Why?
| | Microglia | 2 | 2019 | 269 | 0.510 |
Why?
| | CHO Cells | 8 | 2019 | 165 | 0.510 |
Why?
| | Disease Management | 2 | 2018 | 650 | 0.510 |
Why?
| | Transverse Sinuses | 1 | 2016 | 9 | 0.500 |
Why?
| | Biomarkers | 13 | 2025 | 4261 | 0.490 |
Why?
| | Registries | 1 | 2025 | 2392 | 0.490 |
Why?
| | Antigens, CD19 | 5 | 2022 | 129 | 0.490 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 134 | 0.490 |
Why?
| | Spinal Cord | 8 | 2023 | 384 | 0.490 |
Why?
| | Cricetulus | 7 | 2019 | 114 | 0.480 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1363 | 0.480 |
Why?
| | Retina | 5 | 2023 | 319 | 0.480 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 53 | 0.480 |
Why?
| | Mice, Inbred C57BL | 14 | 2026 | 5967 | 0.460 |
Why?
| | Male | 54 | 2026 | 72431 | 0.450 |
Why?
| | Mutagenesis | 2 | 2019 | 194 | 0.440 |
Why?
| | Stents | 2 | 2016 | 557 | 0.430 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 46 | 0.420 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 176 | 0.420 |
Why?
| | Optic Atrophy | 2 | 2011 | 8 | 0.410 |
Why?
| | Temporal Arteries | 4 | 2015 | 43 | 0.410 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 154 | 0.410 |
Why?
| | Oligodendroglia | 4 | 2025 | 189 | 0.400 |
Why?
| | Intracranial Hypotension | 2 | 2025 | 62 | 0.390 |
Why?
| | Recurrence | 8 | 2026 | 1136 | 0.390 |
Why?
| | Peptide Fragments | 4 | 2023 | 691 | 0.380 |
Why?
| | Antigens, Viral | 3 | 2015 | 182 | 0.370 |
Why?
| | Flow Cytometry | 9 | 2023 | 1154 | 0.370 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 44 | 0.360 |
Why?
| | Axons | 2 | 2022 | 203 | 0.360 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 115 | 0.350 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 5 | 0.350 |
Why?
| | Autoantigens | 5 | 2025 | 425 | 0.350 |
Why?
| | Visual Acuity | 6 | 2021 | 491 | 0.350 |
Why?
| | Aged | 24 | 2026 | 25955 | 0.340 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 35 | 0.340 |
Why?
| | Hemodynamics | 1 | 2016 | 1113 | 0.340 |
Why?
| | Cricetinae | 6 | 2019 | 296 | 0.340 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 149 | 0.340 |
Why?
| | Gene Targeting | 1 | 2011 | 80 | 0.340 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 101 | 0.330 |
Why?
| | Nerve Degeneration | 1 | 2010 | 48 | 0.330 |
Why?
| | Stilbenes | 1 | 2010 | 33 | 0.330 |
Why?
| | Prospective Studies | 11 | 2025 | 7994 | 0.320 |
Why?
| | Eye Diseases | 2 | 2020 | 95 | 0.320 |
Why?
| | Nerve Regeneration | 1 | 2010 | 58 | 0.320 |
Why?
| | Young Adult | 17 | 2025 | 14122 | 0.320 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 590 | 0.310 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 38 | 0.310 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 21 | 0.300 |
Why?
| | Immune System Phenomena | 1 | 2009 | 3 | 0.300 |
Why?
| | Meningioma | 2 | 2023 | 87 | 0.300 |
Why?
| | Rats | 12 | 2021 | 5570 | 0.290 |
Why?
| | Virus Diseases | 1 | 2011 | 218 | 0.290 |
Why?
| | Cell Survival | 2 | 2019 | 1092 | 0.290 |
Why?
| | Adolescent | 18 | 2024 | 22409 | 0.290 |
Why?
| | Somatosensory Cortex | 2 | 2026 | 43 | 0.290 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 2136 | 0.280 |
Why?
| | Nervous System Diseases | 2 | 2020 | 285 | 0.280 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 104 | 0.270 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 133 | 0.270 |
Why?
| | Neurology | 2 | 2007 | 114 | 0.270 |
Why?
| | Protein Binding | 7 | 2025 | 2243 | 0.260 |
Why?
| | Ophthalmology | 2 | 2007 | 116 | 0.260 |
Why?
| | Cerebral Cortex | 3 | 2023 | 470 | 0.260 |
Why?
| | Antibodies | 3 | 2017 | 396 | 0.260 |
Why?
| | Peptide Library | 5 | 2025 | 91 | 0.260 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 150 | 0.250 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1984 | 0.250 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 26 | 0.250 |
Why?
| | Immunization, Passive | 3 | 2020 | 88 | 0.250 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 47 | 0.250 |
Why?
| | Immunoglobulins | 2 | 2026 | 160 | 0.250 |
Why?
| | Mutation | 6 | 2019 | 4081 | 0.240 |
Why?
| | Corpus Callosum | 1 | 2006 | 72 | 0.240 |
Why?
| | Transcriptome | 4 | 2020 | 1036 | 0.240 |
Why?
| | Antibody Formation | 1 | 2007 | 291 | 0.240 |
Why?
| | Gyrus Cinguli | 2 | 2024 | 96 | 0.240 |
Why?
| | Endothelial Cells | 2 | 2026 | 864 | 0.240 |
Why?
| | Proteomics | 2 | 2012 | 1183 | 0.230 |
Why?
| | Herpes Zoster | 3 | 2015 | 315 | 0.230 |
Why?
| | Atrophy | 2 | 2023 | 199 | 0.230 |
Why?
| | Capillaries | 1 | 2026 | 118 | 0.220 |
Why?
| | B-Lymphocyte Subsets | 2 | 2024 | 79 | 0.220 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 27 | 0.220 |
Why?
| | Syndecan-1 | 4 | 2011 | 43 | 0.220 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2025 | 60 | 0.220 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 24 | 0.220 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 178 | 0.220 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2025 | 73 | 0.220 |
Why?
| | Retrospective Studies | 12 | 2026 | 17149 | 0.210 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 14 | 0.210 |
Why?
| | Acute Disease | 3 | 2018 | 1029 | 0.210 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 44 | 0.210 |
Why?
| | Spastic Paraplegia, Hereditary | 1 | 2024 | 12 | 0.210 |
Why?
| | Cerebellar Ataxia | 1 | 2024 | 13 | 0.210 |
Why?
| | Vascular Remodeling | 1 | 2026 | 203 | 0.210 |
Why?
| | Touch Perception | 1 | 2024 | 17 | 0.210 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 28 | 0.210 |
Why?
| | Consciousness | 1 | 2024 | 34 | 0.200 |
Why?
| | Diagnosis, Differential | 6 | 2023 | 1501 | 0.200 |
Why?
| | Nystagmus, Pathologic | 1 | 2024 | 19 | 0.200 |
Why?
| | Blindness, Cortical | 1 | 2003 | 6 | 0.200 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 79 | 0.200 |
Why?
| | Proteolipids | 1 | 2023 | 28 | 0.200 |
Why?
| | Proteoglycans | 1 | 2004 | 110 | 0.200 |
Why?
| | Paraplegia | 1 | 2024 | 60 | 0.200 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 175 | 0.200 |
Why?
| | Risk Assessment | 4 | 2021 | 3729 | 0.200 |
Why?
| | Epitope Mapping | 4 | 2017 | 60 | 0.190 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 820 | 0.190 |
Why?
| | Cell Proliferation | 4 | 2026 | 2489 | 0.190 |
Why?
| | Seroconversion | 1 | 2023 | 48 | 0.190 |
Why?
| | White Matter | 1 | 2025 | 153 | 0.190 |
Why?
| | Cell Nucleus | 1 | 2026 | 592 | 0.190 |
Why?
| | Immune System | 1 | 2004 | 178 | 0.190 |
Why?
| | Neuroprotection | 1 | 2023 | 45 | 0.190 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2023 | 238 | 0.190 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 147 | 0.190 |
Why?
| | Cells, Cultured | 7 | 2016 | 4110 | 0.190 |
Why?
| | Incidence | 3 | 2025 | 2892 | 0.180 |
Why?
| | Disease Progression | 4 | 2026 | 2847 | 0.180 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2909 | 0.180 |
Why?
| | Vision Disorders | 2 | 2021 | 179 | 0.180 |
Why?
| | Zika Virus | 1 | 2023 | 135 | 0.180 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2184 | 0.180 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1766 | 0.180 |
Why?
| | Hippocampus | 2 | 2021 | 966 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 572 | 0.170 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 496 | 0.170 |
Why?
| | Antibody Affinity | 2 | 2019 | 60 | 0.170 |
Why?
| | Protein Isoforms | 4 | 2017 | 396 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 496 | 0.170 |
Why?
| | Zika Virus Infection | 1 | 2023 | 171 | 0.170 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 203 | 0.170 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 31 | 0.170 |
Why?
| | Comorbidity | 2 | 2024 | 1652 | 0.170 |
Why?
| | Internationality | 2 | 2019 | 154 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 36 | 0.160 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1124 | 0.160 |
Why?
| | Schizophrenia | 2 | 2022 | 443 | 0.160 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 51 | 0.160 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 47 | 0.160 |
Why?
| | Azathioprine | 1 | 2020 | 44 | 0.160 |
Why?
| | Animals, Newborn | 3 | 2018 | 890 | 0.150 |
Why?
| | Visual Pathways | 3 | 2023 | 61 | 0.150 |
Why?
| | Interferon-gamma | 1 | 2023 | 781 | 0.150 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 779 | 0.150 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 37 | 0.150 |
Why?
| | Myelin Proteins | 2 | 2017 | 45 | 0.150 |
Why?
| | Amygdala | 1 | 2021 | 198 | 0.150 |
Why?
| | Cell Separation | 2 | 2015 | 303 | 0.150 |
Why?
| | Viral Vaccines | 1 | 2020 | 107 | 0.150 |
Why?
| | Steroids | 1 | 2020 | 159 | 0.150 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 16 | 0.150 |
Why?
| | Models, Molecular | 3 | 2025 | 1610 | 0.150 |
Why?
| | Prevalence | 2 | 2024 | 2839 | 0.150 |
Why?
| | Child | 13 | 2024 | 22600 | 0.150 |
Why?
| | United States | 3 | 2025 | 16018 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 64 | 0.140 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 10 | 0.140 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 9 | 0.140 |
Why?
| | Treatment Outcome | 11 | 2024 | 11735 | 0.140 |
Why?
| | Oxidoreductases | 1 | 2019 | 95 | 0.140 |
Why?
| | Cell Lineage | 1 | 2020 | 376 | 0.140 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 470 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 166 | 0.140 |
Why?
| | Neurogenesis | 3 | 2016 | 157 | 0.140 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.140 |
Why?
| | Peptides | 2 | 2019 | 989 | 0.140 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 80 | 0.140 |
Why?
| | Point Mutation | 1 | 2019 | 242 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 66 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 464 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Skull Neoplasms | 1 | 2017 | 21 | 0.130 |
Why?
| | Spatial Analysis | 1 | 2017 | 22 | 0.130 |
Why?
| | Sphenoid Bone | 1 | 2017 | 15 | 0.130 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 74 | 0.130 |
Why?
| | Mice, Knockout | 9 | 2017 | 3109 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 552 | 0.130 |
Why?
| | Cohort Studies | 5 | 2022 | 5957 | 0.130 |
Why?
| | Antibodies, Viral | 4 | 2023 | 672 | 0.130 |
Why?
| | Orbital Diseases | 1 | 2017 | 37 | 0.120 |
Why?
| | Albumins | 1 | 2017 | 119 | 0.120 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 106 | 0.120 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 365 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 915 | 0.120 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 86 | 0.120 |
Why?
| | Fibrinogen | 1 | 2017 | 181 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2020 | 770 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5414 | 0.120 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 317 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 480 | 0.120 |
Why?
| | HEK293 Cells | 4 | 2022 | 743 | 0.120 |
Why?
| | Microvessels | 1 | 2017 | 98 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 641 | 0.120 |
Why?
| | Interferon-beta | 2 | 2025 | 92 | 0.120 |
Why?
| | Ethics, Research | 1 | 2015 | 33 | 0.120 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 407 | 0.110 |
Why?
| | Treatment Failure | 1 | 2016 | 365 | 0.110 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 6 | 0.110 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 12 | 0.110 |
Why?
| | Retinal Neurons | 1 | 2015 | 3 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 381 | 0.110 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 16 | 0.110 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 2 | 0.110 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 262 | 0.110 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 849 | 0.110 |
Why?
| | Aged, 80 and over | 8 | 2021 | 8284 | 0.110 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 75 | 0.110 |
Why?
| | Plasma Exchange | 1 | 2014 | 18 | 0.110 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3910 | 0.110 |
Why?
| | Nerve Fibers | 1 | 2015 | 105 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 973 | 0.100 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 111 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2019 | 741 | 0.100 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 268 | 0.100 |
Why?
| | Alanine | 1 | 2015 | 170 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2019 | 0.100 |
Why?
| | Glycine | 1 | 2015 | 186 | 0.100 |
Why?
| | Erythropoietin | 1 | 2014 | 100 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2013 | 19 | 0.100 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.100 |
Why?
| | Fetal Death | 1 | 2013 | 58 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2521 | 0.100 |
Why?
| | Antibody Specificity | 2 | 2011 | 178 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| | Autism Spectrum Disorder | 2 | 2016 | 410 | 0.100 |
Why?
| | Neurons | 5 | 2024 | 1639 | 0.090 |
Why?
| | Biomedical Research | 1 | 2019 | 712 | 0.090 |
Why?
| | Phenotype | 3 | 2020 | 3147 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2201 | 0.090 |
Why?
| | Computer Simulation | 1 | 2017 | 1021 | 0.090 |
Why?
| | Syndrome | 2 | 2019 | 379 | 0.090 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 87 | 0.090 |
Why?
| | Proteome | 2 | 2015 | 515 | 0.090 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 171 | 0.090 |
Why?
| | Exanthema | 1 | 2013 | 84 | 0.090 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 44 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 667 | 0.090 |
Why?
| | Antigens, CD20 | 2 | 2023 | 34 | 0.090 |
Why?
| | Area Postrema | 1 | 2011 | 2 | 0.090 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 7 | 0.090 |
Why?
| | Disability Evaluation | 2 | 2026 | 310 | 0.090 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 15 | 0.090 |
Why?
| | Cranial Sinuses | 1 | 2011 | 16 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 153 | 0.090 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 25 | 0.090 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 109 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.090 |
Why?
| | Fundus Oculi | 1 | 2011 | 89 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2015 | 743 | 0.090 |
Why?
| | Cerebral Angiography | 2 | 2011 | 119 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2026 | 2942 | 0.080 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 82 | 0.080 |
Why?
| | Quality of Life | 1 | 2023 | 3183 | 0.080 |
Why?
| | Brain Mapping | 2 | 2024 | 535 | 0.080 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 8 | 0.080 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 190 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2013 | 252 | 0.080 |
Why?
| | Cell Line | 3 | 2011 | 2821 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 202 | 0.080 |
Why?
| | Spinal Puncture | 1 | 2009 | 18 | 0.080 |
Why?
| | Risk Factors | 4 | 2016 | 10796 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4312 | 0.080 |
Why?
| | Pregnancy | 5 | 2023 | 7122 | 0.070 |
Why?
| | Research Design | 1 | 2015 | 1129 | 0.070 |
Why?
| | Genes | 1 | 2009 | 226 | 0.070 |
Why?
| | Algorithms | 1 | 2017 | 1844 | 0.070 |
Why?
| | Databases, Factual | 1 | 2015 | 1494 | 0.070 |
Why?
| | Brain Injuries | 1 | 2014 | 506 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 7140 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 613 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 51 | 0.070 |
Why?
| | Clone Cells | 3 | 2017 | 263 | 0.070 |
Why?
| | Transfection | 3 | 2018 | 924 | 0.070 |
Why?
| | Optic Disk | 1 | 2008 | 53 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3603 | 0.070 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 29 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 524 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 17 | 0.070 |
Why?
| | Pregnancy Complications | 1 | 2013 | 586 | 0.070 |
Why?
| | Vision, Low | 1 | 2007 | 16 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 551 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 288 | 0.060 |
Why?
| | Health | 1 | 2007 | 81 | 0.060 |
Why?
| | Molecular Biology | 2 | 2009 | 57 | 0.060 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.060 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 6 | 0.060 |
Why?
| | Visual Fields | 1 | 2007 | 116 | 0.060 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 28 | 0.060 |
Why?
| | Measles virus | 1 | 2006 | 21 | 0.060 |
Why?
| | Vitreous Body | 1 | 2007 | 117 | 0.060 |
Why?
| | Bevacizumab | 1 | 2007 | 168 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 116 | 0.060 |
Why?
| | Puerperal Disorders | 1 | 2007 | 37 | 0.060 |
Why?
| | Binding, Competitive | 2 | 2019 | 182 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 37 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2026 | 86 | 0.060 |
Why?
| | Models, Immunological | 1 | 2006 | 100 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 238 | 0.060 |
Why?
| | Injections, Spinal | 2 | 2016 | 120 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5870 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2007 | 366 | 0.060 |
Why?
| | Spatio-Temporal Analysis | 2 | 2016 | 39 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1159 | 0.060 |
Why?
| | Fetus | 1 | 2009 | 800 | 0.050 |
Why?
| | Myelography | 1 | 2025 | 40 | 0.050 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2025 | 56 | 0.050 |
Why?
| | DNA | 1 | 2011 | 1447 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 550 | 0.050 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.050 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3523 | 0.050 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 53 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 286 | 0.050 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 21 | 0.050 |
Why?
| | Risk | 1 | 2007 | 911 | 0.050 |
Why?
| | Touch | 1 | 2024 | 39 | 0.050 |
Why?
| | Child, Preschool | 4 | 2021 | 11790 | 0.050 |
Why?
| | Fistula | 1 | 2024 | 49 | 0.050 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 44 | 0.050 |
Why?
| | Granzymes | 1 | 2024 | 48 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2754 | 0.050 |
Why?
| | Ataxia | 1 | 2024 | 69 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2025 | 220 | 0.050 |
Why?
| | Geniculate Bodies | 1 | 2023 | 22 | 0.050 |
Why?
| | Patient Selection | 1 | 2008 | 727 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2350 | 0.050 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2024 | 71 | 0.050 |
Why?
| | Receptors, IgG | 1 | 2023 | 76 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 221 | 0.050 |
Why?
| | Cerebrovascular Circulation | 1 | 2026 | 289 | 0.050 |
Why?
| | Optic Nerve Neoplasms | 1 | 2023 | 12 | 0.050 |
Why?
| | Headache | 1 | 2024 | 151 | 0.050 |
Why?
| | Eye Abnormalities | 1 | 2002 | 17 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1079 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 93 | 0.050 |
Why?
| | Developmental Biology | 1 | 2002 | 24 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 67 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 156 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 41 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 94 | 0.040 |
Why?
| | Antigens, Surface | 1 | 2022 | 155 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2006 | 1103 | 0.040 |
Why?
| | Eye | 1 | 2002 | 110 | 0.040 |
Why?
| | Primates | 1 | 2022 | 133 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 364 | 0.040 |
Why?
| | Gene Regulatory Networks | 2 | 2015 | 319 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1307 | 0.040 |
Why?
| | Glycoproteins | 1 | 2023 | 353 | 0.040 |
Why?
| | Delphi Technique | 1 | 2023 | 330 | 0.040 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 42 | 0.040 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 8 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3329 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 343 | 0.040 |
Why?
| | Base Sequence | 1 | 2004 | 2177 | 0.040 |
Why?
| | COS Cells | 2 | 2011 | 177 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 366 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1995 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 291 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 488 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 120 | 0.040 |
Why?
| | Aging | 2 | 2024 | 1938 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 98 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 13 | 0.040 |
Why?
| | Serum | 1 | 2019 | 57 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 733 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2015 | 906 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 211 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1811 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 165 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 6 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 44 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 967 | 0.030 |
Why?
| | Transcription, Genetic | 2 | 2016 | 1468 | 0.030 |
Why?
| | Survival Analysis | 1 | 2021 | 1370 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2009 | 371 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 304 | 0.030 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 19 | 0.030 |
Why?
| | Clonal Deletion | 1 | 2017 | 16 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 26 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 21 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3414 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1301 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 169 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 715 | 0.030 |
Why?
| | Craniotomy | 1 | 2017 | 84 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 220 | 0.030 |
Why?
| | Signal Transduction | 2 | 2026 | 5185 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 130 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 146 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2017 | 101 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 6 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1810 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 530 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 207 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 100 | 0.030 |
Why?
| | Neocortex | 1 | 2016 | 49 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2016 | 247 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 835 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 503 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 104 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 382 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 365 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 294 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 573 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 425 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 49 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 452 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 41 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 510 | 0.030 |
Why?
| | Intellectual Disability | 1 | 2016 | 174 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 243 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 381 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 20 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 10 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 42 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 63 | 0.030 |
Why?
| | SOXC Transcription Factors | 1 | 2013 | 9 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 23 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 667 | 0.020 |
Why?
| | Narcolepsy | 1 | 2013 | 25 | 0.020 |
Why?
| | Multigene Family | 1 | 2013 | 210 | 0.020 |
Why?
| | Neurodevelopmental Disorders | 1 | 2016 | 223 | 0.020 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 28 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 7 | 0.020 |
Why?
| | Parkinson Disease | 1 | 2019 | 600 | 0.020 |
Why?
| | Interneurons | 1 | 2013 | 125 | 0.020 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 269 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 465 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 195 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 88 | 0.020 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 121 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 41 | 0.020 |
Why?
| | Vaccination | 1 | 2020 | 1419 | 0.020 |
Why?
| | Phlebography | 1 | 2011 | 41 | 0.020 |
Why?
| | O Antigens | 1 | 2011 | 8 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 198 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 197 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2922 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 300 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 564 | 0.020 |
Why?
| | Genome | 1 | 2013 | 305 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 56 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 335 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 662 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 136 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 232 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 176 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 146 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 222 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1056 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1886 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 128 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 41 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 37 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1705 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 765 | 0.020 |
Why?
| | Water | 1 | 2012 | 468 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2446 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 154 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 250 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 332 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 512 | 0.020 |
Why?
| | Virion | 1 | 2009 | 111 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 762 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 14 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 247 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 466 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 357 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 622 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1251 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1129 | 0.010 |
Why?
| | Glioma | 1 | 2010 | 429 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2045 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 779 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1437 | 0.010 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 8 | 0.010 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 14 | 0.010 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 13 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 732 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1182 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 828 | 0.010 |
Why?
| | Infant | 1 | 2017 | 10023 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2591 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 681 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1742 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1569 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 6041 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|